We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 51

Schering v. Pharmascience, merits of NOC proceeding
  • Gowling Lafleur Henderson LLP
  • Canada
  • January 20 2010

The application under the NOC Regulations was dismissed


Aventis v. Pharmascience; motion to set aside a previous order of prohibition; 2009 FC 915; ramipril; September 15, 2009
  • Gowling Lafleur Henderson LLP
  • Canada
  • September 30 2009

Pharmascience had previously sent an Notice of Allegation (NOA) with respect to a patent to Aventis, resulting in a full hearing and appeal, concluding with an order of prohibition


Janssen-Ortho v. Apotex; motion for a stay; 2009 FCA 250; tramadol and acetaminophen; August 20, 2009
  • Gowling Lafleur Henderson LLP
  • Canada
  • September 30 2009

In the Courts below, Apotex brought a motion to dismiss the application


Federal Court of Appeal upholds denial of innovator profits and refuses to grant damages for future lost market share in first case under s. 8 of the PM(NOC) Regulations
  • Gowling Lafleur Henderson LLP
  • Canada
  • June 5 2009

In September 2008, the Federal Court released its first decision interpreting s. 8 of the PM(NOC) Regulations


Sanofi v. Hospira, merits of a 55.2 proceeding
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 3 2009

The Court refused to grant an Order of Prohibition against Hospira regarding its docetaxel product


Pfizer v. Apotex
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 7 2009

The Court upheld the decision of the Prothonotary refusing further production of ANDS documents


Apotex v. Pfizer
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 27 2009

The Court dismissed a motion by Pfizer for summary judgment in a s.8 proceeding


Canada v. Pharmascience
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 27 2009

The Court of Appeal upheld the decision of the trial judge holding that the generic company was not required to address the patents listed on the patent register against submissions filed after it had purchased its comparator drug


Apotex v. Janssen
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 27 2009

The Court of Appeal overturned the decision of the applications judge in issuing a prohibition order and sent it back for reconsideration


Pfizer v. ratiopharm, motion to intervene in appeal of infringement proceedings
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 3 2009

The Court of Appeal denied BIOTEC Canada’s and Eli Lilly’s leave to intervene in Pfizer’s appeal of the Court’s decision to invalidate a patent for amlodipine